La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

IN8bio Bilan de santé

Santé financière contrôle des critères 6/6

IN8bio possède un total de capitaux propres de $13.6M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $22.5M et de $8.9M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$10.22m
Fonds propres	US$13.62m
Total du passif	US$8.88m
Total des actifs	US$22.50m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 6JH ( $12.7M ) dépassent ses passifs à court terme ( $4.8M ).

Passif à long terme: Les actifs à court terme de 6JH ( $12.7M ) dépassent ses passifs à long terme ( $4.1M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 6JH est sans dette.

Réduire la dette: 6JH n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 6JH dispose d'une piste de trésorerie suffisante pour 5 mois sur la base du dernier rapport flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: 6JH devrait disposer d'une marge de trésorerie suffisante pour 5 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

IN8bio Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

IN8bio, Inc. announced that it expects to receive $12.405547 million in funding

IN8bio, Inc. Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio, Inc. Announces Updated Positive Clinical Data from Both of the Phase 1 Investigator-Sponsored Trials of INB-100 for Hematological Malignancies and INB-200 for GBM

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting

In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024

In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc., Annual General Meeting, Jun 12, 2024

IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

New major risk - Financial position

IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP

New major risk - Shareholder dilution

IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors

IN8bio, Inc.’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting

IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting

IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme

IN8bio, Inc. Announces Positive Preclinical Data Underscoring the Potential of Its DeltEx Gamma-Delta T Cells to Target and Kill Ovarian Cancer

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

High number of new and inexperienced directors

In8bio Announces New Data At Ash Showing 100% of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of Inb-100

IN8bio Announces FDA Clearance to Initiate A Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

High number of new and inexperienced directors

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

High number of new and inexperienced directors

High number of new and inexperienced directors

IN8bio, Inc. Appoints Michael R. Bishop to Its Scientific Advisory Board

Independent Director recently bought €197k worth of stock

IN8bio, Inc. Provides Clinical Update from Ongoing Phase 1 Trial of INB-100

IN8bio, Inc. Appoints Kenneth R. Lamontagne as Senior Vice President, Business Development

IN8bio, Inc. Announces Positive Glioblastoma Multiforme (Gbm) Clinical Updates from the INB-200 Phase 1 Trial Presented At Asco 2022

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio, Inc., Annual General Meeting, Jun 01, 2022

IN8bio, Inc. Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines